Literature DB >> 7081141

Misonidazole enhancement of the action of BCNU and melphalan against human melanoma xenografts.

R D Clutterbuck, J L Millar, T J McElwain.   

Abstract

We investigated the effects of combinations of BCNU and misonidazole, and melphalan and misonidazole on growth delay in two human malignant melanoma xenograft lines grown in immune-deprived mice. Misonidazole on its own had no effect on the growth of these tumors, but combinations of BCNU-misonidazole and melphalan-misonidazole produced greater tumor growth delays than those produced by the cytotoxic drugs alone. This was accompanied by increased weight loss. Misonidazole in combination with melphalan also increases hemopoietic stem cell toxicity, but in the case of BCNU there was no enhancement of bone marrow toxicity at the dose chosen for tumor experiments.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7081141

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  11 in total

1.  Treatment of malignant gliomas in adults with BCNU plus metronidazole.

Authors:  D J Stewart; B Benoit; M T Richard; H Hugenholtz; J Dennery; N Russell; E Peterson; Z Grahovac; G Belanger; J A Maroun
Journal:  J Neurooncol       Date:  1984       Impact factor: 4.130

2.  Altered pharmacokinetics in the mechanism of chemosensitization: effects of nitroimidazoles and other chemical modifiers on the pharmacokinetics, antitumour activity and acute toxicity of selected nitrogen mustards.

Authors:  F Y Lee; P Workman
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

3.  Factors influencing the chemosensitization of melphalan by misonidazole.

Authors:  V S Randhawa; F A Stewart; J Denekamp; M R Stratford
Journal:  Br J Cancer       Date:  1985-02       Impact factor: 7.640

4.  Effect of the nitroimidazole Ro 03-8799 on the activity of chemotherapeutic agents against a murine tumour in vivo.

Authors:  P W Sheldon; P Gibson
Journal:  Br J Cancer       Date:  1984-03       Impact factor: 7.640

5.  Misonidazole protects mouse tumour and normal tissues from the toxicity of oral CCNU.

Authors:  F Y Lee; P Workman
Journal:  Br J Cancer       Date:  1985-01       Impact factor: 7.640

6.  Effect of misonidazole pretreatment on nitrogen mustard-induced DNA cross-linking in mouse tissues in vivo.

Authors:  D Murray; R E Meyn
Journal:  Br J Cancer       Date:  1984-12       Impact factor: 7.640

7.  Enhancement of melphalan-induced tumour cell killing by misonidazole: an interaction of competing mechanisms.

Authors:  M R Horsman; J W Evans; J M Brown
Journal:  Br J Cancer       Date:  1984-09       Impact factor: 7.640

8.  Modification of CCNU pharmacokinetics by misonidazole--a major mechanism of chemosensitization in mice.

Authors:  F Y Lee; P Workman
Journal:  Br J Cancer       Date:  1983-05       Impact factor: 7.640

9.  Enhancement of the DNA cross-linking activity of melphalan by misonidazole in vivo.

Authors:  D Murray; R E Meyn
Journal:  Br J Cancer       Date:  1983-02       Impact factor: 7.640

10.  Structure/activity relationships for the enhancement by electron-affinic drugs of the anti-tumour effect of CCNU.

Authors:  P Workman; P R Twentyman
Journal:  Br J Cancer       Date:  1982-08       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.